Search Results

Results 1 - 10 of 14 for child health. (3.03 seconds)
  • COVID-19 vaccines for 5- to 11-year-olds

    Answers to frequently asked questions as COVID-19 vaccinations roll out for children as young as 5.

  • When can you vaccinate your kids?

    Stanford pediatricians helped conduct clinical trials of COVID-19 vaccines for children. Data from the study will be submitted to the Food and Drug Administration for consideration.

  • Allergies to COVID-19 vaccines mostly mild

    In a study of mRNA-based COVID-19 vaccine doses given at Stanford Medicine, vaccine allergies were rare, mild and mostly triggered by a vaccine additive, not the mRNA.

  • Severe COVID-19, autoantibodies linked

    A study spearheaded by Stanford researchers indicates that at least 1 in 5 hospitalized COVID-19 patients develops new antibodies that attack their own tissue within a week of admission.

  • Tips for kids’ back-to-school anxiety

    Returning to school as the pandemic stretches on may spark anxiety in young students, but there are approaches parents can use to build children’s resilience.

  • Winslow leads national COVID-19 group

    A professor of medicine and former Air Force colonel, Winslow temporarily relocated to Washington to head an interagency group responding to this pandemic and preparing for the next one.

  • Evidence COVID-19 causes brain inflammation

    A detailed molecular analysis of tissue from the brains of individuals who died of COVID-19 reveals extensive signs of inflammation and neurodegeneration, but no sign of the virus that causes the disease.

  • Pandemic worsens kids’ weight woes

    The COVID-19 pandemic has led to a greater incidence of obesity and eating disorders among young people, according to experts at Stanford Children’s Health.

  • Pandemic-linked burnout in pregnancy, neonatal care

    A June 2020 survey showed a sharp increase in burnout linked to the global pandemic among health care providers in maternal-fetal and neonatal medicine.

  • Difference in severe versus mild COVID-19

    A comprehensive study of immune responses to SARS-CoV-2 associates mild disease with comparatively high levels of antibodies that target the viral spike protein. But all antibodies wane within months.